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ABSTRACT 
This thesis describes the fabrication, characterization, and application of radiolabeled 
multifunctional microspheres for Cerenkov luminescence imaging and targeting of angiogenesis 
in cancer and atherosclerosis.  Cerenkov luminescence imaging has gained attention as a new 
type of molecular imaging modality for its potential to bridge optical imaging with nuclear 
imaging.  The engineered microsphere design focuses on intensifying the Cerenkov 
luminescence emission and shifting the emission wavelengths toward the near-infrared for better 
penetration of light in biological tissue.  This includes the use of a high-refractive index oil core 
that increases the intensity of Cerenkov luminescence by lowering the Cerenkov radiation energy 
threshold, as well as near-infrared quantum dots that can be optically excited by Cerenkov 
luminescence and generate higher-wavelength optical emission.  In addition to signal 
enhancement of Cerenkov luminescence, the modification of the microsphere surface is 
addressed through the development of conjugation chemistry of functionalization and 
PEGylation to achieve disease targeting and to improve biodistribution of the agent.  For this 
thesis, the microspheres were applied in several studies that were conducted in both cells and 
animal models.   Emphasis was placed on the application of these microspheres for identifying 
tumor locations and atherosclerotic plaques through multimodal imaging techniques, including 
positron emission tomography, Cerenkov luminescence-excited quantum dot fluorescence 
imaging, and conventional fluorescence imaging.  The effectiveness and the challenges 
associated with in vivo targeting using the microspheres are addressed, and possible solutions are 
discussed.  The fabricated design presented in this thesis has great potential for facilitating future 
improvement and optimization of Cerenkov luminescence imaging in deeper tissue. 
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CHAPTER 1 
INTRODUCTION 
1.1 Multimodal Imaging 
Molecular imaging has become an indispensable tool in research, clinical trials, and medical 
practice in recent years due to the advantage of obtaining molecular information, which offers 
great potentials in drug development and early diagnosis of various diseases [1].  However, every 
imaging modality has its advantages and disadvantages, and to date, none of the current imaging 
methods provides comprehensive medical imaging [2].  To harness the strengths of different 
imaging methods, multimodality imaging has become a highly attractive strategy as it combines 
different imaging methods that can provide more complete information for physicians and 
researchers to gain better understanding of the various kinds of disease. 
Molecular imaging consists a diversified group of modalities, such as magnetic resonance 
imaging (MRI) and computed tomography (CT) that provide anatomical information at high 
resolution [3, 4], and positron emission tomography (PET), single-proton emission computed 
tomography (SPECT), and optical imaging that offer quantitative molecular and functional 
information [1, 4, 5].  Table 1 lists some examples of the current imaging techniques along with 
their pros and cons. 
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Table 1: Characteristics of selected imaging modalities [4, 6-8]. 
 
 
Recently, a number of multimodal imaging techniques have been investigated by many research 
groups, including PET-CT, SPECT-CT, MRI-PET, and MRI-optical imaging [1, 2, 9].  In 
addition to the development of multimodal imaging technology, recent research has also focused 
on the development of multimodal molecular imaging agents [10].  These imaging probes are 
attractive because they can be utilized for multiple imaging modalities, and therefore eliminates 
the necessity for additional agent injection for different imaging techniques. 
Among the different multimodality platforms, the fusion of nuclear and optical methods is 
especially unique as these two modalities can generate complementary molecular information.  
While nuclear imaging is highly sensitive and can provide global information, optical imaging 
has specificity and resolution unparalleled by other imaging methods and can offer molecular 
information at the microscopic level [2, 10].  For this purpose, a combined nuclear-optical 
imaging agent would be invaluable for disease diagnosis and surgical treatment. 
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1.2 Positron Emission Tomography  
Molecular imaging has its roots in nuclear medicine and is in many ways an extension of this 
discipline [6], which focuses on the use of imaging tracers in conjunction with imaging 
technologies.  Among the different types of nuclear imaging techniques, PET has been 
demonstrated to be immensely useful in disease diagnosis in both pre-clinical and clinical 
settings due to its high sensitivity and acceptable spatial resolution [4, 11].   
The principle of image formation adapted by PET relies on the pair of annihilated -rays 
indirectly produced by the positron-emitting radiotracers, including Carbon-11 (11C), Fluorine-18 
(18F), Copper-64 (64Cu), and Oxygen-15 (15O) [4, 6, 12, 13].  Shortly after positrons are emitted 
by the radiotracer during radioactive decays, the positrons will undergo annihilation reaction 
with nearby electrons in tissue [12].  The annihilation reaction generates simultaneous emission 
of two 511-keV -rays that propagate in nearly opposite directions, which are detected by a 
cylindrical ring of detectors consist of scintillation crystals coupled to photo-multiplier tubes.  
The detectors convert -ray energy into visible light, which is turned into electrical signals for 
image reconstruction [6, 14]. 
A large portion of the recent research development on this technology has been focusing on 
refining and re-engineering the molecular probes for applications in oncology and cardiology.  
Examples include utilizing antibodies and molecular peptides to target tumor cells and 
angiogenesis [11, 15].  In addition, PET has also been used for evaluation of atherosclerosis and 
heart disease using both direct imaging of cellular receptors and indirect imaging of reporter 
gene expression [16].  With advances in the technology, PET has been demonstrated as a 
powerful non-invasive technique for producing images and quantitative information about the 
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basic functions of the body for disease diagnosis.  For researchers and clinicians to take full 
advantage of PET, it is necessary to further advance the design of molecular tracers to achieve 
higher target specificity [17, 18]. 
 
1.3 Cerenkov Luminescence Imaging  
A recent development in the field of nuclear medicine and imaging technology has been the 
ability to visualize the radioactive decay signals from the medical isotopes, which led to the 
development of Cerenkov luminescence (CL) imaging [19, 20].  CL imaging has become a topic 
in molecular imaging due to its relative low cost compared to existing nuclear imaging 
modalities, such as PET and SPECT.  In addition, CL imaging serves the potential to fulfill the 
purpose of multimodal imaging by bridging nuclear imaging with optical imaging. 
CL imaging uses the principle of Cerenkov radiation generation [21], which is analogous to the 
phenomenon of a sonic boom.  During Cerenkov radiation, the electron distribution in the 
medium is disrupted as the charged particles (positrons or electrons) travel through the medium 
and lose kinetic energy by polarizing the surrounding electrons.  These polarized molecules re-
equilibrate through the emission of ultraviolet (UV) and visible light when the traveling velocity 
of the charged particles exceed the phase velocity of light, giving the observed CL [20, 22].  
Unlike fluorescence emission, CL emission is directional and has a continuous and broad 
spectrum that extends from the UV to the near-infrared (NIR) wavelength range [21].  The 
production of CL can be described using the Frank-Tamm formula [21]. 
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Where dN/dx is the number of photons generated per distance,  is the dimensionless fine-
structure constant (1/137), n is the reactive index, and  is the ratio of the particle velocity to the 
speed of light v/c [21].  Equation (1) shows that CL emission is inversely proportional to the 
wavelengths, suggesting CL emission intensity is stronger in the shorter-wavelength region.  In 
addition, the intensity of CL generated in materials increases with higher index [20-22]. 
The concept of CL imaging was first demonstrated in the pre-clinical setting in 2009, in which 
the study showed that the CL generated from -emitting (both electrons and positrons) isotopes 
can be detected utilizing a sensitive charge-coupled device (CCD) camera [19, 20].  Furthermore, 
several research groups independently showed the feasibility of utilizing CL imaging for disease 
targeting and drug tracking in small animals [23-25].  Unlike fluorescence imaging, since CL 
imaging utilizes approved tracers and therapeutic agents, this technology provides an opportunity 
to bridge the optical (pre-clinical) and nuclear (clinical) gap [26].  In addition, because CL 
imaging does not require large detectors or magnetic systems as with existing nuclear imaging 
techniques, it has higher potential of becoming a more portable system and be utilized in 
intraoperative settings for surgical guidance or real-time feedback [5].  With the maturation of 
this imaging technology, pre-clinical research involving radioisotopes can be further accelerated. 
 
1.4 Quantum Dot Fluorescence 
Quantum dots (QDs) are nanometer-scale light-emitting semiconductor particles that are 
emerging as a new class of fluorescent labels for biology and medicine [27].  In comparison to 
organic fluorophores, QDs have unique optical and electronic characteristics, such as size-
tunable fluorescence emission from visible to IR wavelengths [28].  In addition, QDs have been 
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shown to demonstrate high quantum yields, resistance to photobleaching, and large Stokes shifts.  
Due to their unique optical properties and high level of stability, QDs have been widely utilized 
in the research settings as targeting, imaging and therapeutic agents [28]. 
Recently, QDs have been integrated into CL imaging as a wavelength-converting agent [29].  As 
discussed in the previous section, CL imaging has emerged as an optical technique to track 
radioactive decay signals.  However, one of the limitations of using CL in biomedical imaging is 
that CL emits stronger at shorter wavelengths, which can be strongly attenuated by hemoglobin 
in tissue due to the fundamental optical properties of tissues [29].  This drawback makes CL 
imaging of deeper tissues challenging.  To overcome this limitation, it has been proposed that 
QDs could serve as a suitable CL conversion agent due to their broad continuous UV-blue 
absorption spectrum and high quantum efficiency [30].  In addition, due to the large Stokes shift 
of QDs, their absorption spectrum overlaps with the emission spectrum of CL [27, 30].  
Therefore, QDs can be excited using CL, and the CL emission can be converted to longer 
wavelengths, which are more amenable to deep-tissue imaging [29]. 
One of the advantages of exciting QDs with internally-generated CL is the decreased amount of 
strong background autofluorescence in vivo, which is a disadvantage of QD-based optical 
imaging technology using external excitation [30].  In addition, the use of radioactive isotopes 
provides accessibility for other imaging modalities, including PET and SPECT, in addition to 
optical imaging.  The integration of QDs into CL imaging can potentially benefit the future 
development of CL imaging, and it also opens new opportunities for the application of nuclear-
optical multimodal imaging technology. 
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1.5 Multimodal Protein Microspheres 
Protein microspheres (MS) are micro-sized, biocompatible structure, with an outer shell made 
from disulfide cross-linked bovine serum albumin (BSA) [31].  Microspheres are produced 
through ultrasonic emulsification, and it has been demonstrated that these MSs can be utilized in 
multiple biomedical imaging modalities such as MRI, ultrasound, and optical coherence 
tomography (OCT) [31, 32].  In addition, they can also be used as targeted agents through 
surface modification [32]. 
The previous MS design from the Boppart lab consists of a BSA shell and a vegetable oil core 
that contains Nile red fluorescent dye and iron oxide nanoparticles.  The surface of the MSs was 
functionalized with linear RGD peptides to target the v3 integrin receptor [32, 33].  It has been 
demonstrated that the RGD-labeled MSs can effectively target human cancer cell lines that 
express the v3 integrin [31].  In addition, it has also been shown that the RGD-labeled MSs can 
be utilized for ex vivo targeting of atherosclerotic plaques [34].  The atherosclerotic plaque 
targeting results demonstrate targeting specificity, and the observations were confirmed using 
both magnetomotive optical coherence tomography (MM-OCT) and confocal fluorescence 
microscopy [34].  All of the previous studies have illustrated the high potential of MSs as a 
multimodal imaging agent for disease targeting. 
Integration of two or more imaging techniques could offer the synergistic advantages of each 
modality, and further advancement of multimodal imaging could significantly benefit the 
development of multimodal imaging probe.  It has been shown that MSs have the potential 
versatility as a multimodal imaging agent, but require additional studies to further improve the 
design for in vivo disease targeting. 
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CHAPTER 2  
MULTIMODAL PROTEIN MICROSPHERES 
2.1 Fabrication Chemistry 
The microspheres (MSs) consist of a hydrophobic core and a hydrophilic protein shell made of 
bovine serum albumin (BSA).  The core is composed of organic quantum dots (QDs) that have 
an 800 nm emission peak (Qdot 800 ITC organic quantum dots, Invitrogen), and are suspended 
in vegetable oil (Crisco).  The absorption and emission spectra of the QDs provided by the 
company (Invitrogen) is shown in Figure 1.  The QD-oil suspension for the MS core was 
prepared by first flocculating the QDs from the original solvent (decane).  The QDs stock 
solution was first mixed with four times the volume of the isopropanol/methanol mixture (75/25 
volume ratio) in a sealable test tube.  The mixture was then centrifuged at 3000 rpm for 5 
minutes until a dense brown material was formed at the bottom of the tube.  The supernatant 
fluid was then removed, and the QDs were re-suspended in the vegetable oil. 
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Figure 1: Absorption and emission spectra of Qdot 800 ITC organic quantum dots (Invitrogen). 
 
The process of encapsulating the QD-oil suspension as the core within the BSA shell was 
mediated through sonication, utilizing high-frequency ultrasound delivered by a sonication 
apparatus [32].  The sonication setup is shown in Figure 2.  
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Figure 2: The sonication setup for MS fabrication. 
  
 The BSA shell cross-links through the reduction of disulfide bonds by the radicals formed 
during the sonication process [31].  In the sonication process, a layer of the QD-oil mixture was 
added to the 5% BSA solution in a 1:4 (oil/BSA) ratio in the reaction vessel.  Ultrasound was 
applied to the oil/BSA interface at a frequency of 20 kHz using an acoustic horn at an acoustic 
power of 35 W/cm2 [32].  The reaction vessel was kept in a temperature-controlled water bath at 
45°C throughout the process.  Following the sonication, the MS emulsion was repeatedly washed 
with cold 5% BSA solution and centrifuged at 5000 rpm for 3 minutes to remove excess 
reagents.   
Before labeling the MSs with 64Cu radionuclide, MSs were first washed with 1% PBS at pH 7.4 
and centrifuged at 5000 rpm for 3 minutes to remove excess BSA to avoid unwanted side 
reactions.  After the washing, a solution of 64CuCl2 (Washington University, St. Louis, MO) in 
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ammonium acetate containing the 64Cu radionuclides was added to the MS solution, and the 
mixture was incubated at 30°C for one hour.  After the incubation, the MS solution was filtered 
using 0.22 m centrifuge tube filters (Corning Costar Spin-X) to remove unlabeled 
radionuclides.  The 64Cu-labeled MSs were re-suspended in 1% PBS at pH 7.4.  Figure 3a 
illustrates a schematic of the MSs, and the morphology of the MSs is demonstrated by the 
scanning electron microscopy (SEM) and transmission electron microscopy (TEM) images in 
Figure 3b and 3c, respectively. 
 
Figure 3: 64Cu-labeled QDs MS. (a) Schematic. (b) SEM image of the MSs. (c) TEM image of the shell 
of a MS showing QDs encapsulated within the shell/core.  Scale bar: (b) 2 m. (c) 200 nm. 
 
The average size of the MSs was measured to be approximately 1.52±1.07 (SD) m with a 
median size of 1.19 m using a Coulter counter (Beckman Coulter, Inc.), and the size 
distribution is presented in Figure 4. 
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Figure 4: Size distribution of MSs. 
 
To further confirm that the QDs are encapsulated in the MSs and not in the suspension fluid, the 
suspension of MSs was centrifuged at 500 rpm for 3 minutes to separate the MSs and the 
suspension fluid, and the two phases were imaged using a fluorescence dark box (Maestro, CRi, 
Inc.) equipped with a 445-490 nm excitation filter and an 800 nm cut-in emission filter.  Figure 5 
shows that the fluorescence signals were only detected in the MSs and not in the suspension 
fluid.   
 
Figure 5: Fluorescence dark box images of MSs after separated from the suspension fluid. (a) Bright 
field image. (b) Fluorescence image. (c) Composite image of bright field image and fluorescence signals. 
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2.2 First-Generation RGD-Functionalized Microspheres 
Integrin receptors are integral membrane proteins on the surface of almost all types of cells in the 
body, and they play an important role in angiogenesis and cancer metastasis [35, 36].  Targeting 
cells that overexpress certain integrin receptors is a promising strategy for disease targeting [36].  
Among the various kinds of integrin receptors, the v3 integrin receptor is known to be 
overexpressed in the newly formed vasculature around the tumor sites and in atherosclerotic 
lesions [36-38].  The arginine-glycine-aspartate (RGD) tri-peptide sequence has been widely 
used for targeting the v3 integrin receptor [36, 39], and this peptide was chosen for the 
targeting study.  To prepare the MSs for targeting the newly-formed vasculature in angiogenesis, 
the MSs were functionalized with the RGD peptide ligand (KKKKKKRGD) [31].  The first-
generation targeted MSs were functionalized with linear RGD peptide, which has a chemical 
structure shown in Figure 6. 
 
Figure 6: Chemical structure of linear RGD peptide [40]. 
 
The linear RGD peptide was prepared in 1% PBS solution in 1 mg/mL concentration, and the 
RGD peptide was attached to the MSs using the layer-by-layer method.  This method utilizes the 
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advantage of the surface characteristics of the MSs and the RGD peptide.  Since the polylysine 
chain that RGD attached to was positively charged and the BSA shell of the MSs was negatively 
charged, the RGD peptide was attached to the MS surface through electrostatic interaction [31].  
To utilize the layer-by-layer labeling method, the MSs were first washed with 1% PBS solution 
to remove excess BSA protein, the MSs were then incubated with the RGD peptide solution for 
one hour.  Afterward, the MSs were washed with fresh 1% PBS two to three times to remove 
unlabeled RGD peptides.  Figure 7 shows the schematic of the linear RGD-functionalized MSs. 
 
Figure 7: Schematic of first generation linear RGD-functionalized MSs. 
 
The functionalized MSs were also sized by the Coulter counter, and the size distribution was 
measured to be similar to that measured prior to the functionalization process.  The in vitro and 
in vivo targeting results of the first-generation linear RGD-functionalized MSs are detailed in the 
later chapters. 
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2.3 PEGylation 
It is well known that the biological activities of contrast agents depend heavily on the surface 
chemistry of the agents [41].   As the surface charge of the agents deviate from neutral, they will 
become a target of opsonization, which is the first step in the phagocytic process followed by 
macrophage scavenging, and will result in increased clearance by the biological system [41-43].  
However, a higher in vivo targeting can be achieved by increasing the in vivo circulation of the 
agents [44].  To prevent macrophages scavenging and prolong circulation time in vivo, the 
surface of the agents are often modified by incorporating passivation ligands, such as 
polyethylene glycol (PEG), to protect the agents from the mononuclear phagocytic system [42].  
PEGylation can inhibit the adsorption of opsonin proteins via steric repulsion forces, and 
therefore delaying opsonization [42, 43].  The chemical structure of PEG chain is illustrated in 
Figure 8, and the length of the chain is adjustable. 
 
Figure 8: Chemical structure of polyethylene glycol (PEG) chain. 
 
In an attempt to protect the protein MSs from phagocytosis and to lengthen the blood circulation 
time of the MSs, the MS surface is modified by coating the MSs with a PEG layer.  To assess the 
effect of PEGylation on MS blood circulation time, two parameters were tested: the length of 
PEG chain and the labeling ratio.  The results were evaluated through an in vivo biodistribution 
study. 
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Length of PEG chain 
Two different PEG lengths were examined to investigate the effect of length on blood circulation 
time of MSs: methyl-(PEG)8 (CH3-PEG8, Thermo Fisher Scientific) with molecular weight of 
509.4 Da and methyl-(PEG)5k (CH3-PEG5k, Jenkem, U.S.A.) with molecular weight of 5000 Da.  
Both types of PEG have a non-reactive methyl functional group at one end and an amine-reactive 
N-Hydroxysuccinimide (NHS) functional group at the opposite end for the labeling reaction with 
the BSA shell of MSs.  The MSs were first washed with 1% PBS solution at pH 8, and the PEG 
reagent were prepared by dissolving the reagent in an organic compound, dimethylformamide 
(DMF, Sigma-Aldrich).  After the PBS washing, the MSs were incubated with the PEG reagent 
solution at room temperature for one hour.  Following the incubation, the MS suspension was 
centrifuged at 5000 rpm and 2°C for 3 minutes to separate the MSs from the suspension fluid, 
which contained the unlabeled PEG reagent.  The subnatant fluid was then removed, and the 
MSs were re-suspended in 1% PBS at pH 7.  After PEGylation, the MSs can be labeled with 
64Cu isotope using the same method described in Section 2.1.  Figure 9 illustrates the schematic 
of the 64Cu-labeled PEGylated MSs. 
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Figure 9: Schematic of CH3-PEG8 QD MS. 
 
The MS blood circulation time was tested through a biodistribution study using a rat model 
(Wistar-Furth rat).  Approximately 1 mL of 109 64Cu-labeled PEGylated MSs was injected into 
the rat through the jugular vein and allowed to circulate in vivo for 4 hours.  Two groups of MSs 
at equal concentration were prepared and investigated: PEG8 MSs and the PEG5k MSs. 
After injection of the MS, a dynamic PET-CT scan was conducted during the first hour of 
circulation using a microPET-SPECT-CT scanner (Siemens Healthcare) to record the initial 
uptake of the MSs.  The animal was euthanized at the end of the 4-hour circulation, and selected 
organs and blood sample were extracted and processed using a gamma well counter (Wizard2, 
PerkinElmer) to determine the final biodistribution. 
Blood samples extracted post-mortem were also measured using the gamma well counter.  A 
noticeable difference in the remaining dose was observed between the two groups.  As shown in 
Figure 10, the percent of injected dose (% ID/g) from the PEG5k group was approximately three-
fold higher than that from the other group, which potentially indicated that there was a higher 
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concentration of MSs remaining in the circulation.  This observation suggests that a longer PEG 
chain will extend the blood circulation time of these MSs. 
 
Figure 10: Comparison of remaining percent injected dose (% ID/g) in blood between PEG8 and PEG5k 
based on gamma well counting. 
 
MS-to-PEG labeling ratio 
In addition to the length of the PEG chain, the effect of the labeling ratio between the MSs and 
PEG reagent on circulation time was also evaluated.  NHS-(PEG)5k-CH3 was chosen for this part 
of the study as it was determined to be more effective at prolonging the blood circulation time, as 
discussed in the previous section.  The labeling procedure was the same as described in the 
previous section, and the experimental setup and the sample preparation were also identical to 
the previous study. 
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The NHS group at one end of the PEG reagent is reactive to the amine group (NH2) on the BSA.  
In this part of the study, two different labeling ratios (NH2:PEG), 1:1 and 1:8 were tested and 
compared.  The concentration of BSA protein in 1 mL of 109 MSs was first measured using the 
Lowry protein assay, which is a widely used standard procedure for examining protein 
concentration [45].  The same in vivo biodistribution study procedure as the previous study was 
performed, and the MS blood circulation time was compared based on the remaining dose in the 
extracted blood sample, as measured by the gamma well counter. 
Figure 11 shows the dose comparison between the two groups.  It was found that the remaining 
dose in blood is approximately two-fold higher using the higher labeling ratio (1:8).   
 
Figure 11: Comparison of the remaining dose in blood between 1:1 and 1:8 NH2-PEG labeling ratio 
based on gamma well counting. 
 
20 
 
This result showed that the concentration of PEG on the MS surface also played an important 
role in the in vivo circulation time, which is reasonable as a higher concentration of PEG reagent 
can potentially protect the contrast agent from the opsonin proteins more efficiently. 
Based on the results from these two studies, it was determined that using the CH3-(PEG)5k has a 
greater impact on increasing the in vivo circulation time.  Comparing the remaining dose in blood 
using PEG5k MSs to that using non-PEGylated MSs, the difference between the two was 
approximately three folds, as shown in Figure 12. 
 
Figure 12: Comparison of the remaining dose in blood between no PEG and PEG5k (1:8) based on 
gamma well counting. 
 
In addition, further comparison of the dynamic uptake of MSs based on dynamic PET-CT scans 
also suggests the in vivo circulation time was increased.  All PET-CT scans were acquired from 
the same animals from the previous comparison study shown in Figure 12.  Figure 13 shows the 
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first 30 minutes of MS uptake in the right ventricle of heart, which is a measure of dose in the 
blood as large volumes of blood is stored in the ventricle [43]. 
 
Figure 13: Dynamic MS uptake in the right ventricle based on dynamic PET-CT scan. 
 
Comparing the uptake trend of non-PEGylated MSs and that of PEGylated MSs (PEG5k, 1:8 
labeling ratio), it can be seen that the PEGylated MSs show a slower clearance of the MSs from 
the blood (Fig. 13, red line).  This observation suggests that there were more PEGylated MSs 
than non-PEGylated MSs remaining in the blood circulation system after 30 minutes. 
In addition, changes in the dynamic uptake of MSs in both the liver and the spleen were 
observed.  For the non-PEGylated MSs, the accumulation of the percent injected dose in the liver 
reached a peak after approximately three minutes, and the dynamic trend quickly decreased 
afterward, as shown by the black line in Figure 14.  This behavior suggests a fast liver uptake of 
the MSs and a fast MS clearance from the liver that are likely due to macrophage scavenging of 
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the protein MSs.  In contrast, the PEGylated MSs illustrated a slower increase of percent injected 
dose over time in the liver (Fig. 14, red line), which potentially indicated that the PEGylation 
slowed down the phagocytic process of the MSs. 
 
Figure 14: Dynamic MS uptake in the liver based on dynamic PET-CT scan. 
 
A similar behavior was also observed in the dynamic MS uptake trend in the spleen, as shown in 
Figure 15.  For the non-PEGylated MSs, the accumulation of the percent injected dose reached a 
peak only two minutes after the MS injection and quickly decreased afterward (Fig. 15, black 
line), which was similar to the behavior in the liver.  However, the PEGylated MSs showed a 
slower increase of the accumulation of the injected dose over time (Fig. 15, red line), which 
again suggested that the process of MS clearance was slowed down. 
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Figure 15: Dynamic MS uptake in the spleen based on dynamic PET-CT scan. 
 
The experimental results described in this section show that PEGylation has a noticeable effect 
on the biodistribution of MSs.  The studies on the effect of the PEG chain length and the labeling 
ratio showed that utilizing a longer PEG chain at a high labeling ratio had greater impact on 
increasing the blood circulation time of the MSs.  In addition, it was observed that PEGylation 
changes the dynamic uptake of the MSs in the liver and the spleen, which could indicate that the 
efficiency of the macrophage scavenging process of the MSs is decreased.  These improvements 
on biodistribution as a result of the PEGylation can potentially improve the in vivo targeting 
efficiency by prolonging the in vivo circulation time of the MSs. 
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2.4 Second-Generation PEGylated cRGD-Functionalized Microspheres 
A different MS design was also investigated as it was believed that the weak bonding of 
electrostatic interactions can potentially generate unstable MS surface structure when circulating 
in vivo, and that linear RGD has lower receptor-binding affinity [46].  An alternative labeling 
mechanism: covalent bonding of cyclic RGD with the BSA shell, was applied, which has been 
shown to have higher affinity to the integrin receptor compared to the linear RGD peptide [46].  
To incorporate this new method and the PEGylation with the MSs, NHS-PEG5k-maleimide 
(MAL) PEG compound (Jenkem, U.S.A.) was chosen to replace the NHS-PEG5k-CH3 compound 
since the methyl functional group was a terminal end which cannot be additionally modified.  In 
addition, cyclo(Arg-Gly-Asp-D-Phe-Cys) (cRGDfc, Peptide International) was utilized, which 
contains the thiol functional group (-SH) that can covalently bond to the MAL group on the PEG 
chain.  The chemical structure of cRGDfc peptide is presented in Figure 16. 
 
Figure 16: Chemical structure of cRGDfc peptide (Peptide International). 
 
The PEGylation procedure using the NHS-PEG5k-MAL compound was identical to the NHS-
PEG5k-CH3 procedure described in the previous section.  For the thiol group on the cRGDfc to 
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bond to the MAL group on the PEG chain, the thiol group was first activated using a reducing 
agent, tris (2-carboxyethyl)phosphine (TCEP). cRGD powders were first dissolved in 1% pH 7.4 
PBS solution at 1 mg/mL concentration.  A reducing agent, TCEP-HCl crystals (sigma Aldrich), 
was then added to the cRGDfc solution, and the solution was incubated at room temperature for 
30 minutes.  To label the PEGylated MSs with the cRGD peptides, the PEGylated MSs 
suspended in 1% pH 7.4 PBS solution were combined with the activated cRGDfc and incubated 
for 30 minutes.  After the incubation, the MS suspension was centrifuged at 5000 rpm and 2°C 
for three minutes to separate the functionalized PEGylated MSs from the suspension fluid that 
contains the free peptides.  The MSs were then isolated and re-suspended in 1% pH 7.4 PBS 
solution.  After the functionalization step, MSs were labeled with 64Cu isotope using the same 
procedure as described previously.  Figure 17 illustrates the schematic of 64Cu-labeled 
PEGylated cRGD-functionalized MS. 
 
Figure 17: Schematic of 64Cu-labeled cRGD-functionalized PEGylated QD MS. 
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CHAPTER 3 
CERENKOV LUMINESCENCE AND CERENKOV 
LUMINESCENCE-EXCITED QUANTUM DOT FLUORESCENCE 
3.1 Cerenkov Luminescence Characterization 
It is known that CL has a continuous emission spectrum that extends from the UV into the blue 
wavelength range, and the luminescence intensity is strongest in the 350 – 500 nm region [21].  
To have a better understanding of the nature of CL and how it can be utilized in this MS study, a 
number of characteristic studies were conducted using the 64Cu isotope since it was used for MS 
labeling.  64Cu is a commonly used positron-emitting isotope for PET imaging with a half-life of 
approximately 12.7 hours [22, 25].  In addition, this isotope generates sufficient radioactive 
decay energy (653 keV) to emit CL [25].  Furthermore, comparing to other medical isotopes, 
64Cu provided easier labeling chemistry with the protein shell MSs, as discussed in the previous 
chapter. 
The relationship between CL intensity and the radioactivity was first investigated.  Since higher 
radioactivity leads to higher integrations per second [47], the number of charged particles 
traveling at sufficient speed for CL to occur is potentially higher.  To illustrate this concept, 64Cu 
isotope was suspended in 1% PBS solution in serial dilutions in a 96-well plate, as illustrated in 
Table 2. 
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Table 2: Experimental setup of CL intensity vs. radioactivity study (PBS). 
 
 
The wellplate containing the samples was imaged using a luminescence-sensitive dark box 
(Stanford Photonics, Inc.) equipped with an emission filter wheel for CL imaging.  Samples were 
imaged for one minute under a short pass (< 500 nm) emission filter.  Results showed that CL 
intensity increases linearly with increasing radioactivity (Fig. 18). 
 
Figure 18: CL intensity increased linearly with increasing radioactivity in PBS medium. (a) CL image of 
64Cu solution in serial dilutions in PBS. (b) CL intensity comparison shows that CL intensity increases 
with increasing radioactivity. 
 
The same relationship study was also performed using vegetable oil as the medium, which is 
similar to the MS design.  The experimental conditions are illustrated in Table 3. 
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Table 3: Experimental setup of CL intensity vs. radioactivity study (vegetable oil). 
 
 
A well of 100% total activity was not prepared as the PBS study because the isotope was 
dissolved in ammonium acetate and would be difficult to isolate from the solution.  The samples 
were imaged using the same dark box as the previous experiment, and it was observed that 
changing the medium does not affect the linear relationship, as shown in Figure 19. 
 
Figure 19: CL intensity increased linearly with increasing radioactivity in vegetable oil. (a) CL image of 
64Cu solution in serial dilution in vegetable oil. (b) CL intensity comparison illustrates that CL intensity 
increases with increasing radioactivity. 
 
In addition, further comparison of the two studies showed that CL emission was stronger in the 
vegetable oil than in the PBS at the same radioactivity (Fig. 20).  This observation suggested that 
CL emission increases with higher refractive index of the medium since vegetable oil has a 
higher refractive index (n = 1.46) than PBS (n = 1.33) [48].  This result is consistent with 
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previous studies [26], and can also be observed in the Frank-Tamm formula (Eq. 1) discussed in 
Chapter 1.  CL is emitted when charged particles travel faster than the phase velocity of light in 
the medium, and the speed of light decreases with increasing index of the medium [21, 49].  
Since the velocity threshold is lower, the probability of charged particles emitted from the 
radioactive decay traveling faster than the threshold increases, suggesting more CL would be 
emitted. 
 
Figure 20: CL intensity is higher in vegetable oil than that in PBS. 
 
This preliminary characterization of the CL demonstrated that the 64Cu isotope generates 
detectable CL, and the CL intensity increases linearly with increasing radioactivity.  In addition, 
the results demonstrated the positive relationship between CL intensity and refractive index 
characterized in previous studies. 
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Additional CL characterization was also performed using the 64Cu-labeled MSs to examine 
whether the addition of MSs affected the basic CL properties that were observed in the previous 
studies, which only utilized the isotope.  The MSs used in this part of the study do not yet 
contain any QDs, to ensure pure CL emission.  To investigate the effect of MS concentration on 
CL intensity, 64Cu-labeled vegetable oil MSs were prepared in serial dilutions using 1% PBS and 
imaged using the luminescence dark box for one minute under the short pass (< 500nm) emission 
filter.   
 
Figure 21: CL image of 64Cu-labeled vegetable oil MSs in serial dilution shows that CL intensity from 
the MSs increases with increasing concentration. 
 
It was found that the CL intensity increases linearly with increasing MS concentration (Fig. 21), 
which was the same as the previous study using 64Cu isotope only.  In addition, the relationship 
between CL intensity and refractive index was examined using MSs with different types of 
hydrophobic cores.  The three different core liquids chosen were fluorocarbon (Fluorinert 
electronic liquid FC-43, 3M), vegetable oil, and wintergreen oil (methyl salicylate, Sigma-
Aldrich) with refractive indices of 1.25, 1.46, and 1.54, respectively [48].  The three types of 
MSs were fabricated using the same sonication procedures as described in Chapter 2, but without 
the QDs.  64Cu-labeled MS samples (100 L) were prepared in equal concentration and dose, and 
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the samples were imaged using the luminescence dark box for one minute under the short pass 
emission filter.  Results are shown in Figure 22. 
 
Figure 22: Intensity of CL from MSs increases with higher refractive index of the core. (a) CL image of 
MSs with different core materials. Left to right: fluorocarbon (n = 1.25), vegetable oil (n = 1.46), and 
wintergreen oil (n = 1.54). Concentration: 107 MSs/mL in all samples; dose: 130 Ci in all samples.   
(b) CL intensity comparison illustrates the positive relationship between CL intensity and refractive 
index. 
 
Results showed a significant difference in CL intensity among the three types of MSs, which 
agreed with the previous observation.  It was also noticed that CL intensity does not increase 
linearly with increasing index (Fig. 22b).  Although the Frank-Tamm formula (Eq. 1) suggests a 
nonlinear relationship between the Cerenkov radiation energy and the refractive index, more data 
points are required to further characterize the relationship between the CL intensity and the 
refractive index of the MS core materials.  However, the increase in light output with higher 
refractive index is consistent with the reduction in the speed of the propagation of light in the 
medium and an amplification of the Cerenkov radiation [21].   
The CL characterization study using 64Cu isotope demonstrated the basic properties of CL, 
including the relationship between the CL intensity and the radioactivity and the relationship 
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between the CL intensity and the refractive index.  Further study using the 64Cu-labeled oil MSs 
showed that the addition of MSs does not affect these basic properties of CL.  These 
observations suggest that the design of the 64Cu-labeled MSs produces more CL than 64Cu 
isotope alone by utilizing a higher-index medium (vegetable oil). 
 
3.2 Cerenkov Luminescence-Excited Quantum Dot Fluorescence 
In this study, the objective was to utilize CL as an optical excitation source to generate QD 
fluorescence in the NIR range since the additional QD fluorescence can contribute to the amount 
of light emitted at longer wavelengths, which penetrate through tissue more efficiently [29].  To 
evaluate the properties of CL-excited QD fluorescence, characterization studies were done using 
64Cu-labeled QD MSs. 
To examine the effect of QDs on the optical emission spectrum, Both 64Cu-labeled QD MSs and 
64Cu-labeled vegetable oil MSs (no QDs) at equal levels of radioactivity were prepared in serial 
dilutions and imaged using the luminescence dark box under both the short pass (< 500 nm) 
emission filter and the long pass (> 600 nm) emission filter for one minute each.  The short pass 
filter blocked emission greater than 500 nm, and the long pass filter allowed only wavelengths of 
600 nm and above to be detected.  Figure 23 shows the optical emission from the two types of 
MSs under both filters.  The optical signal intensity increased with higher MS concentrations as 
observed previously under both emission filters.  In addition, the optical signal from the QD MSs 
was higher under the long pass emission filter (Fig. 23a), while the signal from the oil MSs 
(without QDs) was higher under the short pass emission filter (Fig. 23b).  Since pure CL 
emission shows stronger intensity in the shorter wavelengths similar to the oil MSs emission in 
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Figure 23b [26], the results from this study suggested that the addition of QDs in the MS core 
shifts the optical emission from the MSs toward longer wavelengths.  In addition, it was 
observed that under the short pass filter, the optical signals from the QD MSs were significantly 
reduced (Fig. 23a top row) compared to those from the oil MSs (Fig 23b top row).  This 
reduction in signal intensity is potentially due to radiation energy emitted from the 64Cu isotopes 
being absorbed by the QDs as an optical source for fluorescence emission, which contributed to 
the optical signals at longer wavelengths. 
 
Figure 23: 64Cu-QD MSs emitted stronger optical signals under the long pass (> 600 nm) emission filter, 
while 64Cu-oil MSs (without QDs) emitted stronger optical signals under the short pass (< 500 nm) 
emission filter. (a) 64Cu-QD MSs under both the short pass (top) and the long pass (bottom) emission 
filters. (b) 64Cu-oil MSs under both the short pass (top) and the long pass (bottom) emission filters. 
 
Since longer wavelengths of light suffer less attenuation by hemoglobin in the tissue [29], it was 
hypothesized that MSs containing the NIR QDs and higher index oil would yield more optical 
signals at longer wavelengths than 64Cu isotopes alone, and thus could be more readily detected 
through biological tissue.  To verify this hypothesis, approximately 200 L of 64Cu-QD MSs and 
64Cu solution at equal level of radioactivity (approximately 20 Ci) were injected 
subcutaneously into a shaved mouse that was previously sacrificed.  The 64Cu-QD MSs were 
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compared directly against the 64Cu isotope solution because many previous studies utilized only 
the isotopes for CL imaging [21, 24, 29].  The two injection sites were separated by an 
appropriate distance (2 cm) to avoid mixing of the two samples.  The mouse body carrying the 
two samples was imaged using the luminescence dark box with the long pass filter, shown in 
Figure 24. 
 
Figure 24: 64Cu-QD MSs illustrated higher optical signals than 64Cu alone at longer wavelengths under 
the mouse back skin. (a) Optical signals from the two locations on the back of the mouse. (b) Composite 
image of optical signals and the bright field image. 
 
It was found that at equal radioactivity, 64Cu-QD MSs produce four-fold stronger signal than 
64Cu alone through the skin.  This observation suggested that utilizing both a high-index (greater 
than the refractive index of tissue) oil core and the QDs increases the optical emission intensity 
through the skin at longer wavelengths, and can potentially improve CL imaging in deeper tissue. 
Initial characterization studies on CL and CL-excited QD fluorescence showed the linear 
relationship between the CL intensity and radioactivity of the isotopes and the positive 
relationship between the CL intensity and the refractive index of the medium.  In addition, it was 
shown that the presence of MSs does not affect the basic properties of CL, and the MS design 
appeared to have positive impact on the optical signal strength of CL imaging at longer 
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wavelengths.  These observations suggest that 64Cu-QD MSs are potential suitable agent for CL 
imaging of disease in deeper tissue. 
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CHAPTER 4 
IN VITRO MICROSPHERES CELL TARGETING 
4.1 First-Generation Microspheres Cell Targeting 
As discussed in Chapter 2, the first-generation targeted MSs were functionalized with linear 
RGD for targeting.  To examine the targeting efficiency of the first generation MSs, in vitro cell 
targeting was performed using the human colorectal adenocarcinoma epithelial cell line, HT-29 
(ATCC).  This cell line was chosen because it can be targeted using the RGD peptides, as 
demonstrated in previous studies [31, 39].  Three experimental groups were designed as shown 
in Table 4: control group with 1% PBS solution, linear RGD targeted MSs, and non-targeted 
bare MSs.  The MSs used for the cell targeting study were not labeled with 64Cu isotopes since it 
did not directly associate with the effectiveness of targeting. 
Table 4: Experimental setup of first-generation MSs using HT-29 cell line. 
 
The cells were seeded the day before the targeting experiment, and a single layer of cells was 
ensured.   Cells were incubated with the designated agents at room temperature for one hour 
followed by three clean PBS washes.  Each cell dish was then imaged using an inverted 
fluorescence microscope (Axiovert 200, Zeiss), and both the bright field and the fluorescence 
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images were acquired to assess the targeting efficiency.  The average fluorescence was 
calculated from six different locations on the cell dishes, and a t-test was also performed to 
determine to statistical significance.  Figure 25 shows the result of the targeting experiment.  The 
control group showed no fluorescence, indicating the cells did not generate autofluorescence that 
would potentially interfere with the actual fluorescence.  Both the targeted and the non-targeted 
groups showed fluorescence, but the fluorescence intensity from the targeted group was 
approximately three-fold higher than the non-targeting group, as illustrated in Figure 26. 
 
Figure 25: First generation MS cell targeting using HT-29 cell line illustrates higher level of targeting 
using the targeted MSs. Bright field: top; fluorescence: bottom. (a, d) Control. (b, e) Targeted MSs.  
(c, f) Non-targeted MSs. Scale bar: 20 m, applies to all images. 
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Figure 26: Fluorescence intensity comparison from HT-29 cell targeting shows significantly higher 
fluorescence intensity from the targeted group. All values are in mean ± SD. 
 
In addition, individual MSs were also observed on top of the cells, as shown in the bright field 
images in both the targeted and non-targeted groups (Fig. 25b and c), which suggested that the 
MSs bind to the top of the cells.  The presence of MSs in the non-targeted group was most likely 
due to the particles being trapped among the cells, or non-specific binding.  
The in vitro cell testing results illustrate that targeting utilizing the linear RGD-functionalized 
MSs is feasible.  The large difference in fluorescence intensity suggests that first-generation 
linear RGD-functionalized MSs show good targeting efficiency in cells. 
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4.2 Second-Generation Microspheres Cell Targeting 
After the second-generation PEGylated cRGD-functionalized MSs were designed, cell targeting 
efficiency was also performed.  Three different types of cell studies were performed using 
different cell lines.  The first study was done using human umbilical vein endothelial cells 
(HUVEC, Lonza), which was shown to express the v3 integrin [50].  The second study was 
conducted on a human breast adenocarcinoma epithelial cell line, MDA-MB-231 (ATCC), and 
the last study was performed using a different type of human breast adenocarcinoma epithelial 
cell line, MCF-7 (ATCC).  These two breast cancer cell lines were chosen because they were two 
cancer cell lines with different levels of expressions of the v3 integrin [39, 50, 51].  The results 
from these three different cell experiments yielded information about the targeting efficiency and 
specificity of the second-generation cRGD-functionalized MSs. 
HUVECs are endothelial cells that are known to express the v3 integrin [50], and therefore are 
a suitable cell line for evaluating the efficiency of targeting angiogenesis.  The experimental 
setup is detailed in Table 5.  PEG-cRGD MSs stands for PEGylated targeted MSs and PEG-MSs 
stands for PEGylated non-targeted MS. 
Table 5: Experimental setup of MS cell targeting using HUVEC cells. 
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The cell preparation and incubation procedures were identical to the procedure for HT-29 cell 
experiment described in the preceding section.  After incubation, the cells were washed with 
clean PBS and imaged using the inverted fluorescence microscope to assess the fluorescence 
intensity.  The level of targeting was determined based on the average fluorescence of six 
different locations on the cell dishes, and a t-test was also performed.  The results are shown in 
Figure 27. 
 
Figure 27: Second-generation MS cell targeting using HUVECs demonstrate high level of targeting using 
the targeted MS. Bright field: top; fluorescence: bottom. (a, d) Control. (b, e) PEGylated targeted MSs. 
(c, f) PEGylated non-targeted MSs. Scale bar: 20 m, applies to all images. 
 
Similar to the first-generation study, a significant difference in fluorescence intensity was 
observed between the targeted and the non-targeted groups.  The fluorescence intensity measured 
from the targeted group was approximately three-fold higher than that from the non-targeted 
group, as demonstrated in the plot in Figure 28.  In addition, clusters of MSs were observed in 
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the bright field images in Figure 27b, which contributed to the saturating fluorescence signals 
seen in the corresponding fluorescence image (Fig. 27e).  Diffuse fluorescence from endocytosed 
or degraded MSs was also observed in the cytoplasm of these cells, which was not attributed to 
autofluorescence, given the absence of autofluorescence in the control sample (Fig. 27d).  The 
HUVEC MS targeting results suggest that the new design of the second-generation PEGylated 
targeted MSs does not alter the targeting ability.  
 
Figure 28: Fluorescence intensity comparison from the HUVEC cell targeting shows higher fluorescence 
intensity from the targeted group. All values are in mean ± SD. 
 
The second study was done using the MDA-MB-231 cell line, which was a breast cancer cell 
line that was known to express the v3 integrin [39, 50, 51].  The experimental procedures and 
setup were identical to the HUVEC study.  Results are shown in Figure 29. 
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Figure 29: Second generation MS cell targeting using MDA-MB-231 cell line demonstrates high level of 
targeting using the targeted MSs. Bright field: top; fluorescence: bottom. (a, d) Control. (b, e) PEGylated 
targeted MSs. (c, f) PEGylated non-targeted MSs. Scale bar: 20 m, applies to all images. 
 
Figure 29 shows that similar to the previous cell studies, the targeted group illustrates stronger 
fluorescence than the non-targeted group (Fig. 28 e, f).  In addition, it was found that the 
fluorescence intensity from the targeted group was significantly higher than that from the non-
targeted group (Fig. 30).  This observation shows that the v3 integrin targeting mechanism is 
applicable to both cancer and non-cancer cell lines, suggesting that this method can be utilized to 
target diseases that contains the process of angiogenesis such as cancer and atherosclerotic lesion 
formation [37, 52].  In addition, both the HUVEC and the MDA-MB-231 studies suggest that the 
MSs show good targeting efficiency in vitro. 
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Figure 30: Fluorescence intensity comparison from the MDA-MB-231 cell targeting shows higher 
fluorescence intensity from the targeted group. All values are in mean ± SD. 
 
The last cell study used the MCF-7 cell line, which was a type of human breast cancer cell line 
that does not express the v3 integrin [39].  The purpose of this study was to examine the non-
specific targeting of cRGD-functionalized MSs by utilizing a cell line that did not express this 
particular integrin receptor.  The average fluorescence intensity of each experimental group was 
calculated using the same method as described in the previous cell studies.  Figure 31 shows the 
MCF-7 cell targeting results. 
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Figure 31: Second-generation MS cell targeting using MCF-7 cell line demonstrates low targeting across 
all groups. Bright field: top; fluorescence: bottom. (a, d) Control. (b, e) PEGylated targeted MSs.  
(c, f) PEGylated non-targeted MSs. Scale bar: 20 m, applies to all images. 
 
Fluorescence imaging of the cells showed weak to no fluorescence across all groups, as shown in 
Figure 31d-f.  In addition, comparison of fluorescence intensity revealed no significant 
difference between the targeted and the non-targeted groups (Fig. 32).  This result suggested that 
MSs did not target the cells, and the fluorescence was most likely from the trapped and degraded 
MSs.  The MCF-7 cell targeting study shows that the cRGD-functionalized MSs does not target 
the cell lines without the v3 integrin receptors. 
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Figure 32: Fluorescence intensity comparison from the MCF-7 cell targeting shows low fluorescence 
intensity in all groups, and no significant difference in signal intensity between targeted and non-targeted 
groups. 
 
Cell studies of both the first-generation linear RGD-functionalized MSs and the second-
generation PEGylated cRGD-functionalized MSs show good in vitro targeting contrast.  
Furthermore, studies of the second-generation MSs using different types of cell lines suggest that 
the MSs also show good targeting specificity, and illustrate better targeting on cells that express 
the v3 integrin. 
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CHAPTER 5 
IN VIVO TARGETING, BIODISTRIBUTION, AND 
MULITMODAL IMAGING 
5.1 First-Generation Microspheres Tumor Targeting 
Normal cells transform into tumor cells when certain genetic mutations occur, which causes the 
cells to stop responding to anti-growth signals from specific proteins and become immortal [53].  
These mutated tumor cells and tumor masses continue to grow and survive through self-
sustaining angiogenesis, which is the induced outgrowth of new blood vessels from pre-existing 
vasculature systems, in order to receive sufficient oxygen and nutrients [53-55].  In these newly-
formed blood vessels, the v3 integrin receptors are known to be overexpressed by the 
endothelial cells [56, 57], and the purpose of this in vivo tumor study was to target the v3 
integrins around the tumor sites utilizing the MSs. 
All tumor targeting experiments were performed using the N-methyl-N-nitrosourea (NMU) 
induced rat mammary tumor model since this rat tumor model has been previously shown to 
overexpress the v3 integrins, and can be targeted using the RGD peptides [58].  Female 
Wistar-Furth rats were injected intraperitoneally with the NMU carcinogen at a concentration of 
55 mg/kg at 25 and 35 days of age.  The injection volume varied from 0.2 to 0.4 mL.  Mammary 
tumors were allowed to grow for 6 to 8 weeks after the second NMU injection. 
The first in vivo tumor targeting study was done using the first-generation linear RGD-
functionalized MSs (targeted: n = 3; non-targeted: n = 3).  After the animal was anesthetized, 
approximately 1 mL of 109 64Cu-labeled MSs at 500 Ci was injected into the jugular vein.  An 
47 
 
in vivo 30-minute dynamic microPET-CT scan was initiated at the start of the injection to track 
the dynamic MS uptake in the mammary tumors.  After the PET-CT scan, the animal was 
sacrificed, and selected organ and tumor samples were collected for ex vivo dark box imaging.  
All tissue samples were also measured by the gamma well counter after the dark box imaging to 
assess the dose of the 511 keV annihilated gamma rays in each sample.  To evaluate the targeting 
efficiency in vivo, the non-targeted MSs were also tested to compare the level of targeting 
between targeted and non-targeted MSs. 
 
5.1.1 Targeted Microspheres  
Figure 32 shows the whole-body scan generated from the microPET-CT.  Signals were detected 
at the tumor locations indicated in the top row of Figure 33, suggesting the presence of MSs.  In 
addition, the dynamic uptake of MSs around the tumor locations demonstrated a steady increase 
over time (Fig. 34), which suggests accumulation of MSs. 
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Figure 33: Whole-body microPET-CT scan of the mammary tumor-bearing rat from the targeted study 
shows PET signals at the tumor sites (30 minutes after injection). Red and white arrows: tumors; green 
arrow: liver; blue arrow: kidney. Top row: PET; bottom row: PET-CT. (a) Axial view. (b) Coronal view. 
(c) Sagittal view. Scale bar: 1 cm, applies to all images. 
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Figure 34: Dynamic MS uptake in the mammary tumor (indicated by the red arrow in Figure 32) based 
on PET shows increasing MS accumulation over time. All tumors showed similar MS uptake behavior. 
 
Strong background signals were also observed from the main organs including the liver and the 
kidneys (Fig. 33b, green and blue arrows, respectively), suggesting that the majority of the MSs 
are trapped in these organs potentially due to macrophage scavenging [43].  Previous studies 
have found a positive relationship between phagocytic rate and the particle size, and particles 
between 2-3 m demonstrate the highest rate [59].  Since the average size of the MSs is 
approximately 2 m (Ch. 2, Fig. 4) and not PEGylated, the MSs would be quickly recognized by 
macrophages and internalized.   
Two types of dark box imaging were utilized for the ex vivo imaging of selected tissue samples.  
The tissues were first imaged in the luminescence dark box (Stanford Photonics, Inc), and then 
imaged using the fluorescence dark box (Maestro, CRi) to verify the results acquired from the 
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luminescence dark box.  For CL-excited QD fluorescence imaging, all samples were imaged for 
5 minutes in the luminescence dark box under the long pass (> 600 nm) emission filter to collect 
CL-excited QD fluorescence signals.  Figure 35 shows the CL-excited QD fluorescence image of 
the tumor.  The original gray scale signal image was processed using Matlab by applying a 
median filter to remove the background noise and improve the signal-to-noise ratio.   
 
Figure 35: CL-excited QD fluorescence image of the right groin tumor from the targeted MS study. Scale 
bar: 3 mm. 
 
The same tumor was then imaged using the fluorescence dark box equipped with a 445-490 nm 
excitation filter and an 800 nm emission filter, shown in Figure 36.  This specific set of filters 
was chosen to match the absorption and emission spectra of the QDs (Ch. 2, Fig. 1).  
Fluorescence was detected from the tumor, which was consistent with the result from CL-excited 
QD fluorescence imaging.  The correlation between these two optical imaging modalities 
suggests the presence of targeted MSs around the tumor. 
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Figure 36: QD fluorescence image of the right groin tumor from the targeted MS study. (a) Fluorescence 
image. (b) Composite image of the fluorescence and the bright field image. Scale bar: 3 mm, applies to all 
images. 
 
All tissue samples were also measured using the gamma well counter (GWC) to assess the 
biodistribution of MSs and to verify the PET signals, illustrated in Figure 37.  The 
biodistribution plot shows that the lungs, liver, spleen, and cortex of the kidneys have the highest 
amount of radioactivity, which is consistent with what was observed from the PET scan.  The 
large accumulation in these organs could be largely due to macrophage scavenging, change of 
surface charge of the MSs, or larger MSs being trapped in the organs.  In addition, it was 
observed that the amount of radioactivity at the tumor is higher than the background such as the 
blood and the skin (Fig. 37), which suggests MS uptake around the tumor.  Overall, this in vivo 
targeted study demonstrates consistent results across all imaging modalities. 
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Figure 37: Biodistirbution of first generation targeted MSs based on gamma well counting illustrates 
high percent injected dose in the lungs, liver, spleen, and cortex of kidneys.  Small accumulation is also 
observed around the tumor. 
 
 
5.1.2 Non-Targeted Microspheres 
Non-targeted studies were also carried out using the bare non-functionalized MSs, and the 
injection and the imaging procedures were identical to the targeted study.  The in vivo 
microPET-CT scan shown in Figure 38 illustrates higher signals in the liver and the kidneys.  In 
addition, the PET scan showed minutely weaker signal at the tumor location compared to the 
targeted study, and this observation was further confirmed by the dynamic MS uptake 
comparison around the tumor between targeted and non-targeted studies (Fig. 39).  Figure 39 
illustrates that the targeted group shows higher uptake and accumulation around the tumor. 
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Figure 38: Whole-body microPET-CT scan of the mammary tumor-bearing rat from the non-targeted 
study shows weaker PET signals at the tumor sites (tumors indicated by arrowed). Top row: PET; bottom 
row: PET-CT. Signal intensity is normalized between Figure 38 (non-targeted) and Figure 33 (targeted). 
(a) Axial view. (b) Coronal view. (c) Sagittal view. Scale bar: 1 cm, applies to all images. 
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Figure 39: Dynamic MS uptake comparison between targeted and non-targeted MSs shows slightly 
higher accumulation in the targeted group. 
 
Figure 40 illustrates the CL-excited QD fluorescence image of the left groin tumor from the non-
targeted study.  The signal intensity from the targeted and the non-targeted studies was measured 
across 7 locations, and a t-test was also performed to determine the statistical significance.  It 
was found that the signal intensity from the non-targeted study is weaker than that in the targeted 
study, as seen in the intensity comparison shown in Figure 41.  The observation suggests that 
fewer non-targeted MSs accumulated at a tumor site compared to the targeted MSs.  The binding 
of the non-targeted MSs was possibly due to non-specific binding. 
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Figure 40: CL-excited QD fluorescence image of the left groin tumor from the non-targeted MS study. 
Scale bar: 3 mm. 
 
 
 
Figure 41: CL-excited QD fluorescence intensity comparison at a mammary tumor between the targeted 
and the non-targeted studies shows higher optical signal intensity in the targeted group. 
 
The same tumor sample was also imaged using the fluorescence dark box, which is shown in 
Figure 42.  The fluorescence intensity was averaged across 7 locations for the targeted and the 
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non-targeted studies, and a t-test was also performed.  Similar to previous imaging results, QD 
fluorescence was detected from the tumor sample but was weaker than that from the targeted 
study as shown in the chart in Figure 43.  Both optical imaging modalities show that the tumor 
from the targeted group shows stronger optical signal than the non-targeted group.  In addition, 
signal intensity comparison illustrates that the signal intensity from the targeted group is 
significantly higher than the non-targeted group.  However, high levels of non-specific binding 
was observed in the non-targeted study, which were potentially caused by larger MSs being 
trapped in the small capillaries, and can contribute to a portion of the optical signals observed in 
both targeted and non-targeted groups.   
 
Figure 42: QD fluorescence image of the left groin tumor from the non-targeted study. (a) Fluorescence 
image. (b) Composite image of the fluorescence and the bright field image of the tumor. Scale bar: 3 mm, 
applies to all images. 
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Figure 43: QD fluorescence intensity comparison at a mammary tumor between the targeted and the non-
targeted studies shows higher signals in the targeted group. 
 
In addition, further radioactivity measurement of the tumor samples using the GWC showed 
higher level of radioactivity in the targeted group, but large amount of non-specific binding was 
also detected in the non-targeted group, as illustrated in Figure 44.  This observation is consistent 
with the results obtained from the optical imaging.  Preliminary in vivo tumor targeting studies 
using the first-generation MSs show that while there was a significant difference in the level of 
targeting between targeted and non-targeted MSs, a high level of non-specific binding was also 
observed. 
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Figure 44: Remaining injected dose comparison based on gamma well counting at a mammary tumor site 
between the targeted and the non-targeted studies shows the targeted group contains higher accumulation 
of radioactivity than the non-targeted group. 
 
5.2 Second-Generation Microspheres Tumor Targeting 
In vivo tumor targeting study was also performed using the second-generation PEGylated cRGD-
functionalized QD MSs.  The purpose was to examine whether the protected MS surface and 
higher-affinity cRGD improve the targeting.  The same NMU rat tumor model was utilized, and 
the MSs were allowed to circulate in vivo for one hour instead of 30 minutes.  Longer MS 
circulation time was used to allow more time for integrin receptor binding and clearance process 
to occur.  The MS injection dose and the imaging procedures were kept the same.  In addition to 
the PEGylated cRGD-functionalized MSs, the PEGylated MSs (non-targeted) were also tested to 
examine the targeting contrast and the level of non-specific binding. 
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5.2.1 Targeted Microspheres 
The cRGD-functionalized MSs were injected through the jugular vein and allowed to circulate 
for one hour while the animal was under the anesthesia.  After one hour, a post-mortem 
microPET-CT scan was performed.  Dynamic PET-CT was not performed since the effect of 
PEGylation on biodistribution was already examined as discussed in Chapter 2.  Figure 45 
illustrates the post-mortem PET-CT scan of the tumor-bearing rat.  Results show clear PET 
signals at the tumor site, but strong background signals in the main organs, which is similar to 
the previous in vivo studies. 
 
Figure 45: Whole-body microPET-CT scan of the tumor-bearing rat from the targeted study shows PET 
signals at the tumor sites (tumors indicated by arrowed). Top row: PET; bottom row: PET-CT. (a) Axial 
view. (b) Coronal view. (c) Sagittal view. Scale bar: 1 cm, applies to all images. 
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After the PET-CT scan, the tumor was excised from the animal for CL-excited QD fluorescence 
imaging in the dark box.  Figure 46 shows the CL-excited QD fluorescence image of the tumor.  
The original gray scale image was processed the same way as the first-generation MS tumor 
study as described in the previous section, and visible CL-excited QD fluorescence was observed 
in the tumor. 
 
Figure 46: CL-excited QD fluorescence image of the excised tumor from the targeted study. (a) CL-
excited QD fluorescence image (b) Composite image of the signals and the bright field image of the 
tumor.  Scale bar: 1 cm, applies to all images. 
 
The same piece of tissue was then imaged using the fluorescence dark box to examine the 
presence of QD fluorescence and to verify the CL-excited QD fluorescence imaging.  QD 
fluorescence was detected from the tumor as shown in Figure 47, which was consistent with the 
observation in CL-excited QD fluorescence imaging.  The correlation between the two optical 
imaging modalities suggests that MSs are present in the tumor tissue. 
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Figure 47: QD fluorescence image of the excised tumor from the targeted study. (a) Fluorescence image. 
(b) Composite image of the signals and the bright field image of the tumor.  Scale bar: 1 cm, applies to all 
images. 
 
In addition, selected organs along with the tumor tissue were measured by the GWC to evaluate 
the MS biodistribution, as shown in Figure 48.  The results indicated that high background signal 
is still detected from the main organs, including the liver and kidneys.  Also, comparison of the 
percent injected dose between the first-generation targeted MS biodistribution (Fig. 37) and the 
second-generation targeted MS biodistribution (Fig. 48) shows similar level of radioactivity.  
This observation suggests that the amount of MS uptake is approximately the same between the 
first-generation and the second-generation MSs.  
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Figure 48: Biodistribution of the second-generation targeted MSs based on gamma well counting. 
 
5.2.2 Non-Targeted Microspheres 
An in vivo circulation study was also performed utilizing the PEGylated non-targeted MSs, 
which were labeled with NHS-PEG-CH3 compounds using the same protocol described in 
Chapter 2.  MSs were injected in vivo through the jugular vein and allowed to circulate for one 
hour.  Afterward, the animal was euthanized and subjected to post-mortem PET-CT scan 
followed by ex vivo CL-excited QD fluorescence dark box imaging and fluorescence dark box 
imaging.  The biodistribution of the PEGylated non-targeted MSs was also determined using the 
GWC. 
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The PET-CT scan did not show a significant difference in signal intensity at the tumor site 
compared to the previous PEGylated targeted MSs.  High level of radioactivity was detected in 
the liver and the kidneys, while a lower level of activity was detected at the tumor site, 
suggesting a small amount of MS binding around the tumor. 
The tumor tissue and selected organs were then excised and imaged using the luminescence dark 
box for CL-excited QD fluorescence imaging.  Figure 49 shows the CL-excited QD fluorescence 
image of the excised tumor tissue.  The optical signal intensity was normalized to that from the 
previous targeted study, and the resulting image showed some differences in signal intensity 
compared to the targeted study (Fig. 49).  Further quantitative comparison and statistical analysis 
of the signal intensity illustrated that the optical signal intensity from the targeted group was 
approximately 1.7-fold higher than the non-targeted, and this difference was statistically 
significant (Fig. 50).  However, a high level of non-specific binding was still detected from the 
non-targeted group, similar to the previous first-generation non-targeted MS study. 
 
Figure 49: CL-excited QD fluorescence image of the excised tumor from the non-targeted study. (a) CL-
excited QD fluorescence image (b) Composite image of the signals and the bright field image of the 
tumor.  Scale bar: 1 cm, applies to all images. 
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Figure 50: CL-excited QD fluorescence intensity comparison at the tumor between the second-generation 
targeted and non-targeted MSs shows higher signal intensity in the targeted group. 
 
The same tumor tissue was also subjected to GWC and compared to the targeted study (Fig. 51).  
Similar to the result of dark box imaging, the difference in percent injected dose was small 
compared to the targeted study, and the MS uptake at the tumor sites was similar to the first 
generation MS study.   
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Figure 51: Biodistribution of the second-generation non-targeted MSs based on gamma well counting. 
 
Overall, the results of tumor targeting using the second-generation PEGylated MSs did not show 
significant improvement as hypothesized.  One of the potential explanations could be the size of 
the MSs.  It was found that particles with larger diameter (> 200 nm) cannot escape from the 
phagocytic process as efficiently as smaller particles [60], causing the high background signals 
from the main organs.  In addition, previous biodistribution studies of protein MSs also observed 
significant accumulation of MSs in organs such as liver and spleen [61].  Larger MSs can also 
potentially be trapped in the smaller blood vessels around the tumor, which can decrease the 
targeting contrast between the targeted and the non-targeted MSs, and increase the level of non-
specific binding of the non-targeted MSs.  In future studies, the fabrication method can possibly 
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be modified to reduce the size of the MSs, and additional in vivo studies can be conducted to 
investigate the effect of size on MS biodistribution and tumor targeting.   
In addition to the size of the MSs, an unexpected challenge was encountered in the second-
generation MS targeting studies, which also potentially affected the targeting efficiency of the 
MSs.  The group of rats utilized for this tumor study developed tumors at a significantly slower 
rate compared to the previous studies.  In the first-generation MS tumor studies, the rat model 
began to develop mammary tumors approximately 6 weeks following the second NMU injection, 
and the tumors grew beyond 1 cm in size two weeks afterward.  In the second-generation MS 
tumor studies, signs of tumor development on the rats were not observed until approximately 10 
weeks following the second NMU injection.  In addition, many of the tumors only grew to 
approximately 1 cm in size.  This observation could potentially affect the MS targeting since the 
level of v3 integrin expression depends heavily on the size of the tumors [58].  Previous 
studies have shown that the tumors developed on NMU-induced rat mammary tumor model 
show higher expression of v3 integrin after reaching 1 cm or larger in size [58].  Therefore, 
smaller tumors would likely result in lower level of MS targeting.  The cause of smaller tumors 
in the rats used for the second-generation MS study could be an inherent variability between 
animals, and will need to be confirmed through additional in vivo studies. 
 
5.3 Second-Generation Microspheres Atherosclerotic Lesions Targeting 
In addition to the newly formed vasculature around tumors, it is known that the v3 integrin is 
also overexpressed in atherosclerotic lesions [35].  Atherosclerosis is a type of arteriosclerosis, 
which is a disease that causes alterations in the arterial vessel wall [62].  The disease is 
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categorized as atherosclerosis when the infected areas localize in the large- and medium-sized 
arteries such as the aorta, which causes hardening, thickening, and loss of elasticity of the vessel 
wall [62].   
To study MS targeting of atherosclerosis, the second-generation PEGylated cRGD-
functionalized MSs were also tested in a hyperlipidemic rodent model (Wistar-Furth rats; 
targeted: n = 3; non-targeted: n = 2).  The animals were fed with either regular rat chow (control 
animals) or a high-lipid rat chow with a high dose of D2 vitamin (disease animals) to induce 
atherosclerotic lesions.  The lesions are found to localize in the aortic root and are characterized 
by the presence of increased level of cholesterol and macrophages [63].  After prolonged feeding 
of the high-lipid diet, the collection of cellular debris and collagen would be observed in the 
aorta [63]. 
MS injection quantity and dose were identical to the tumor study.  A 1 mL solution of MSs (109 
MSs/mL) labeled with approximately 500 Ci of 64Cu isotopes was injected into the animal 
through the jugular vein and allowed to circulate for one hour.  A post-mortem microPET-CT 
scan was then performed followed by ex vivo dark box imaging and gamma well counting.  Both 
targeted and non-targeted MSs were tested to examine the targeting contrast. 
 
5.3.1 Targeted Microspheres 
A PET-CT scan (Fig. 51) shows clusters of PET signal around the aortic arch, above the heart.  
Due to the lack of CT contrast in the soft tissue, the location of the heart and the arch is not as 
readily apparent.  However, by comparing to a reference CT scan of the heart of a rat that 
contains a radiographic contrast medium, Omnipaque 350 (350 mg/mL of iodine), the heart and 
68 
 
the arch were able to be identified, and the signals were observed around the arch when overlaid 
with the PET scan.  The presence of PET signals around the arch suggested the potential 
accumulation of MSs at this site. 
 
Figure 52: Close-up sagittal PET-CT scan of a hyperlipidemic rat from the targeted MS study. The heart 
is identified by the back arrow in both the PET-CT (left) and the CT (right) scans. PET signals on the 
aortic arch are indicated by the red arrows in the PET-CT scan. Scale bar: 1 cm, applies to all images. 
 
For ex vivo optical imaging, the entire aorta starting from the aortic root to the abdominal region 
was dissected out of the sacrificed animal, and the aorta was washed thoroughly with clean PBS 
to remove all blood clots and unbound MSs before ex vivo imaging.  Figure 53 shows the CL-
excited QD fluorescence image of the dissected aorta.  The tissue sample was imaged using the 
luminescence dark box under the long pass (> 600 nm) emission filter for 5 minutes.  A median 
filter was applied to the image, and it was observed that concentrated signal spots can be located 
along the aorta. 
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Figure 53: CL-excited QD fluorescence image of the rat aorta from the targeted study. Clusters of optical 
signals are detected along the aorta. (a) CL-excited QD fluorescence image. (b) Composite image of the 
CL-excited QD fluorescence and the bright field image of the aorta. Scale bar: 1 cm, applies to all images. 
 
The aorta was further image using the fluorescence dark box for the presence of QD 
fluorescence, shown in Figure 54.  The fluorescence imaging showed similar features as the CL-
excited QD fluorescence imaging, and the signal locations from the two imaging modalities were 
comparable.  The signal locations did not exactly match due to re-positioning of the aorta and 
different sensitivity levels between the two systems.  In addition, portions of the QD 
fluorescence signals can potentially come from degraded MS core contents, which did not 
contain the CL source, and will not necessarily produce CL-excited QD fluorescence. 
 
Figure 54: QD fluorescence image of the rat aorta from the targeted study. (a) Fluorescence image.  
(b) Composite image of the fluorescence and the bright field image. Scale bar: 1 cm, applies to all 
images. 
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Comparing the results from both types of dark box imaging, it appears that the targeting occurred 
mostly in the arch region of the aorta where the aorta connects to the heart [43].  The observation 
suggests the possible presence of atherosclerotic lesions, but this observation requires histology 
to confirm.  Sections of the flushed aorta from different regions and the blood sample were also 
measured by GWC to compare the accumulation of radioactivity in the aorta and that in the 
blood.  Figure 55 illustrates the dose comparison based on GWC counts. 
 
Figure 55: Comparison of dose accumulation in aorta sections and blood sample show the arch contains 
the highest dose. 
 
GWC measurement shows that the accumulation of radioactivity in the arch section and the 
abdominal aorta section is approximately 60% higher than the radioactivity in the blood sample, 
which suggests potential presence of the targeted MSs accumulated at these locations after the 
PBS flush.  In addition, it was noticed that these two locations of the aorta coincide with where 
CL-excited QD fluorescence signal was observed, as shown in Figure 53.  To verify the 
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observations from the ex vivo imaging, histology was performed on the sections of the signal-
rich regions.  One of the investigated areas was the aortic arch.  Tissue samples were fixed in 
formalin, paraffin embedded, and sectioned at 5 m thickness.  All the tissue sections were then 
stained using the hematoxylin and eosin stain (H & E stain) and examined by a pathologist 
blinded to the imaging results. 
One of the sections was obtained from the upper aorta where no signal was observed as indicated 
in Figure 56a.  The histology section is presented in Figure 56b, which shows the histological 
appearance of a normal aorta.  The normal arterial intima is a thin layer of connective tissue lined 
by a layer of endothelial cells that appears compact and stratified [43, 62].  This observation is 
consistent with the lower GWC counts and optical signals found in the upper aorta. 
 
Figure 56: Histology section of a segment of the upper aorta shows the normal morphology of the arterial 
intima. (a) Sectioning location is identified by a white line. (b) H & E stain of the tissue section shows the 
well-stratified intima layer without accumulation of foam cells. Scale bar: 100 m. 
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Another sectioning location was chosen from the aorta arch, where CL-excited QD fluorescence 
signal, QD fluorescence signal, and GWC counts were obtained.  Figure 57a shows the 
sectioning location, and Figure 57b shows the corresponding histology image.  Thickening of the 
intima was observed along with signs of early-stage fibrous plaque [62], which contain 
accumulation of macrophage foam cells and collagen fiber, as indicated in Figure 57b [64].  The 
presence of MSs was not visible in the histological sections since they could be washed off 
during the tissue fixation and staining process.  The results from both the imaging and the 
corresponding histology suggest that the 64Cu-labeled cRGD-functionalized PEGylated QD MSs 
accumulate at regions of atherosclerosis. 
 
Figure 57: Histology section of a segment of the arch shows the thickening of the intima and the foam 
cells. (a) Sectioning location is identified by a white line. (b) H & E stain of the tissue section shows 
early-stage fibrous plaque (arrowed). Scale bar: 25 m. 
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5.3.2 Non- Targeted Microspheres 
The same experimental procedures were performed again using the PEGylated non-targeted MSs 
at the same injection quantity and dose.  After the MSs were injected through the jugular vein 
and allowed to circulate for one hour, a post-mortem microPET-CT scan was acquired followed 
by ex vivo dark box imaging and gamma well counting.  The PET-CT scan revealed weak signals 
around the arch, compared to the targeted study. 
The entire aorta was then dissected out and cleaned thoroughly with fresh PBS for dark box 
imaging.  Figure 58 shows the CL-excited QD fluorescence image of the aorta.  The tissue 
sample was imaged using the same system setup as the targeted study, and the image was 
processed using the same method.  It was found that the average signal intensity from the entire 
aorta is lower than that from the targeted MS study.  The signal intensity from the targeted and 
the non-targeted studies was measured across 7 locations, and a t-test was performed to 
determine the statistical significance. It was found that the signal intensity from the targeted 
study is approximately three-fold higher than that from the non-targeted study, as shown in 
Figure 59. 
 
Figure 58: CL-excited QD fluorescence image of the aorta from the non-targeted study shows weak 
optical signals overall. (a) CL-excited QD fluorescence image. (b) Composite image of the CL-excited 
fluorescence and the bright field image of the aorta. Scale bar: 1 cm, applies to all images. 
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Figure 59: CL-excited QD fluorescence intensity comparison on the aorta shows the signal intensity from 
the second-generation targeted MSs to be significantly higher than the non-targeted MSs. 
 
The aorta sample was then imaged using the fluorescence dark box as shown in Figure 60.  The 
fluorescence imaging illustrated similar result as the CL-excited QD fluorescence imaging, in 
which the aorta sample from the non-targeted study showed weaker optical signals.  Both optical 
imaging modalities showed consistent finding that the aorta from the non-targeted study 
illustrated weaker signals compared to that from the targeted study.  This observation suggests 
that the cRGD-functionalized MSs demonstrate stronger targeting of atherosclerosis. 
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Figure 60: Fluorescence image of the aorta from the non-targeted study. (a) Fluorescence image.  
(b) Composite image of the fluorescence and the bright field image. Scale bar: 1 cm. 
 
Similar to the targeted study, sections of aorta samples were also measured using the GWC, and 
the comparison of remaining percent injected dose further showed that the non-targeted samples 
contain smaller amount of radioactivity, suggesting a smaller amount of MS accumulation.  The 
comparison is shown in Figure 61.  In addition, histology was also performed on the aorta in the 
same way as the targeted study to correlate the imaging results and the actual plaque locations. 
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Figure 61: Comparison of remaining dose in the arch between the targeted and the non-targeted studies 
shows the targeted group has higher dose accumulation. 
 
Histology was performed to examine for evidence of atherosclerotic lesions, shown in Figure 62.  
One of the sectioning locations was from the arch, as specified in Figure 62a, which shows weak 
optical signal in both CL-excited QD fluorescence imaging and fluorescence imaging.  However, 
H & E staining of the tissue segment illustrates evidence of fibrous plaques, as illustrated in 
Figure 62b.  Figure 62b shows that the fibrous plaques contain collagen fibers and calcium 
precipitates, which are formed as a result of increased fibrotic response in the intima due to 
accumulation of lipid in foam cells [62, 64].  The non-targeted study shows that the imaging 
results and the histology do not correlate, which suggests that the majority of the optical signal 
obtained is most likely due to non-specific MS binding. 
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Figure 62: Histology section of a segment of the aortic arch where imaging result and histology do not 
match. (a) Histology location is specified by a white line. (b) H & E stain of the tissue section shows 
fibrous plaques containing calcium precipitates (C) and collagen fibers (F). Scale bar 50 m. 
 
In vivo atherosclerotic lesions targeting shows noticeable difference in signal intensity between 
the targeted and the non-targeted studies, which suggests that the cRGD-functionalized MSs 
demonstrate high targeting efficiency toward atherosclerotic plaques.  Consistent observations 
were seen across all imaging modalities, including PET-CT scan, CL-excited QD fluorescence 
dark box imaging, QD fluorescence dark box imaging, and gamma well counting.  In addition, 
the imaging results correlated with the histology.  The histological sections of the aorta where 
optical signal was detected showed signs of fibrous plaques, and it was demonstrated that 64Cu-
labeled cRGD-functionalized PEGylated QD MSs accumulate at regions of atherosclerosis.  The 
atherosclerotic plaque study shows higher targeting contrast than the tumor study most likely due 
to the different locations of the diseases.  The newly-formed vasculature systems around the 
tumors usually contain smaller capillaries, and the larger MSs or aggregates can be physically 
trapped in the vicinity.  In comparison, the aorta has a significantly larger diameter, which allows 
the MSs to pass more easily, and potentially result in higher targeting contrast. 
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CHAPTER 6 
CONCLUSIONS AND FUTURE DIRECTIONS 
The work presented in this thesis describes the fabrication of 64Cu-labeled quantum dot 
microspheres for enhancing the Cerenkov luminescence, for shifting the Cerenkov luminescence 
emission to the near-infrared, and for the application of these microspheres for both in vitro and 
in vivo targeting of the v3 integrin.  The design concept and its effect on Cerenkov 
luminescence emission were addressed and presented.  This included incorporating a high-
refractive index oil core and near-infrared quantum dots, which showed significant improvement 
of optical emission at longer wavelengths.  The surface of the microspheres was also modified 
with PEGylation to achieve longer circulation time in vivo, and the improvement on microsphere 
biodistribution was demonstrated.   
Quantum dot microspheres were also functionalized with cRGD peptides for targeting the v3 
integrin, which is overexpressed during the process of angiogenesis [65].  cRGD-functionalized 
PEGylated quantum dot micropsheres were utilized to target the integrin receptor in vitro in a 
variety of different cell lines.  The targets included HUVEC, MDA-MB-231, and MCF-7 cells, 
and the microspheres demonstrated good targeting efficiency and specificity.  In addition, 64Cu-
labeled cRGD-functionalized PEGylated quantum dot microspheres were used for in vivo 
targeting and imaging of angiogenesis in tumor and atherosclerosis.  The imaging modalities 
utilized in the in vivo study included in vivo PET-CT scanning, ex vivo Cerenkov luminescence-
excited quantum dot fluorescence imaging, and fluorescence imaging.  The tumor study 
demonstrated measurable targeting contrast between the targeted and non-targeted studies, and 
the challenges encountered and possible causes have been addressed.  The atherosclerosis study 
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showed good contrast, and consistent results were obtained across all imaging modalities.  In 
addition, histological analysis was performed, which showed good correlations with the imaging 
results. 
In current clinical settings, there is a lack of real-time feedback for the physicians to acquire 
functional information in the operating room.  Instead, surgeons mostly rely on the ultrasound or 
MRI scans taken prior to the surgery, or a hand-held gamma probe for surgical guidance to 
ascertain the locations of the disease, such as the tumor margins.  Existing imaging modalities 
such as nuclear and optical techniques are not suitable for intraoperative operations since nuclear 
imaging lacks the portability, and there are limited clinically approved molecular probes for 
optical functional imaging [29].  Cerenkov luminescence imaging allows clinically approved 
radionuclides to be detected using the optical method, and can potentially provide functional 
information about the disease in real-time.  In addition to the methods employed in this thesis, 
additional studies on enhancing the penetration depth of Cerenkov luminescence, and eventually 
on developing catheter-based Cerenkov luminescence imaging are needed to extend the 
technology of Cerenkov luminescence imaging into intraoperative imaging.  For microspheres 
the application of this agent can be broadened through further improvements of the agent design 
to achieve better disease detection.  In addition, the therapeutic potentials of the microspheres 
can also be explored for treatment of disease.  While the work presented in this thesis 
demonstrates new methods to improve the optical output of Cerenkov luminescnece imaging 
utilizing multifunctional microspheres, additional studies are required to identify the best way to 
maximize the intraoperative potential of this relatively new imaging modality. 
It has been shown previously that microspheres can be utilized in a variety of imaging 
techniques.  The work presented here further demonstrates the unique and versatile design of 
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these microspheres and their capability of enhancing and shifting the emission of Cerenkov 
luminescence as a contrast signal.  One of the limitations of in vivo Cerenkov luminescence 
imaging has been the low tissue penetration depth of the emitted blue light.  The combination of 
high-index oil core and near-infrared quantum dots in one imaging agent can potentially 
overcome these difficulties, and the fabricated design demonstrated in this work can be 
beneficial for future technological development of in vivo Cerenkov luminescence imaging in 
deeper tissues.  In addition to the improvement in Cerenkov luminescence imaging, these 
microspheres can also potentially be used as a drug delivery capsule for therapeutic purposes due 
to their relatively large volume.  Overall, the microsphere design presented in this thesis is 
valuable for advancing the molecular imaging technology and broadening the range of 
applications of molecular agents for the early detection, diagnosis, and treatment of disease. 
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